PDUFA dates February 2018: FDA calendar and catalysts.
0 PDUFA dates fell in February 2018. The FDA calendar also recorded 8 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
PDUFA dates in February 2018
No PDUFA dates are disclosed for this period as of November 16, 2026.
Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months
February 2018: other FDA decisions and filings
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| February 5, 2018 | Symfi Lo (efavirenz; lamivudine; tenofovir disoproxil fumarate) | VTRS | FDA approval | — | Approved | openFDA Drugs@FDA |
| February 7, 2018 | Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate) | GILD | FDA approval | — | Approved | openFDA Drugs@FDA |
| February 12, 2018 | Symdeko (Copackaged) (ivacaftor; ivacaftor, tezacaftor) | VRTX | FDA approval | — | Approved | openFDA Drugs@FDA |
| February 14, 2018 | Erleada (apalutamide) | JNJ | FDA approval | — | Approved | openFDA Drugs@FDA |
| February 16, 2018 | Imbruvica (ibrutinib) | ABBV | FDA approval | — | Approved | openFDA Drugs@FDA |
| February 22, 2018 | VELCADE® (bortezomib) | PFE | Complete Response Letter | — | CRL issued | FDA Complete Response Letters |
| February 26, 2018 | VERZENIO (abemaciclib) | LLY | FDA approval | — | Approved | openFDA Drugs@FDA |
| February 28, 2018 | Cimduo (lamivudine; tenofovir disoproxil fumarate) | VTRS | FDA approval | — | Approved | openFDA Drugs@FDA |
February 2018: dated readouts
No events in this view.
Questions
What PDUFA dates are in February 2018?
0 PDUFA dates fell in February 2018. The FDA calendar also recorded 8 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
Can these dates change?
Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.